Latest · Article
78% Lower Overdose Risk: The Volkow Study That Shocked Addiction Medicine
NIDA Director Nora Volkow
Commercial pages may contain paid referral links. Compare the full payment terms and licensed-care details before enrollment.
NIDA Director Nora Volkow
Inside the Lähteenvuo registry study from JAMA Psychiatry: semaglutide linked to 36% fewer alcohol-related hospitalizations across 228,000 Swedish patients with AUD. The largest study of…
Live tracker of every clinical trial testing GLP-1 medications for smoking and nicotine cessation. UNC Chapel Hill, UT Houston, Oklahoma, Ottawa — status, design, and what the data means so…
Breakdown of the landmark Wang/Volkow study showing semaglutide associated with 44% reduced risk of cannabis use disorder. Published in Molecular Psychiatry, 2024.
The first RCT of a GLP-1 medication for opioid use disorder. 20 patients, 3 weeks, 40% craving reduction — and some participants reported zero cravings. What the Grigson trial means.
A deep breakdown of the 2025 JAMA Psychiatry randomized clinical trial showing semaglutide reduced alcohol cravings, heavy drinking days, and total consumption in adults with alcohol use…
Can GLP-1 medications help you quit smoking? We review the UNC trial subanalysis, preclinical evidence, active clinical trials, and the reward-pathway mechanism.
What neuroscience says about GLP-1 medications and food noise. Reward circuitry, food addiction research, and how semaglutide changes the brain
Why GLP-1 medications affect multiple addictions: the dopamine connection. Mesolimbic pathways, cross-addiction evidence, and what clinical trials are testing next.
GLP-1 medications for binge eating disorder: clinical evidence, mechanism, and why medication alone isn
The JAMA Psychiatry studies on GLP-1 and alcohol use disorder explained. Swedish registry data, UNC randomized trial, mechanism, and what it means for treatment.
A practical guide to bringing up GLP-1 research with your doctor, whether you
Reports of reduced gambling urges on GLP-1 medications are piling up. But with zero clinical trials and only anecdotal evidence, here
Preclinical research shows semaglutide markedly reduces cocaine-seeking in animal models. A tirzepatide meth trial is already recruiting. Here
Can Ozempic help with addiction? Is semaglutide FDA-approved for alcoholism? Will cravings come back if I stop? 15 questions about GLP-1 medications and substance use, answered with sources.
GLP-1 medications quiet
The largest study yet: 606,000 U.S. veterans on GLP-1 medications showed 14% lower risk of developing any new substance use disorder, plus fewer overdoses, hospitalizations, and deaths.
Tirzepatide (Mounjaro) cut alcohol intake over 50% in rodents via dual GLP-1/GIP mechanism. How does it compare to semaglutide for addiction? The preclinical evidence.
Obesity and addiction share dopamine dysfunction, reward circuit dysregulation, and cross-sensitization. GLP-1 drugs treat both because they target the shared biology of compulsive…
San Francisco launches first human trial of semaglutide for methamphetamine addiction. No FDA-approved meds exist for stimulant use disorders. Here
When people stop GLP-1 medications, appetite returns. Does drug craving rebound the same way? The biggest open question in GLP-1 addiction research, explained.
The first major randomized controlled trial of semaglutide for alcohol use disorder shows significant reductions in heavy drinking days, cravings, and liver biomarkers. Full breakdown of…
People on semaglutide keep saying the same thing: alcohol, cigarettes, and cravings just stopped mattering. It
GLP-1 receptors in the brain
Only 3 medications are FDA-approved for alcohol use disorder. How does semaglutide
Semaglutide users show 32% lower risk of tobacco use disorder. Active NIH trials are testing GLP-1 drugs for smoking cessation. Here
Multiple studies show semaglutide is associated with dramatically lower opioid overdose rates. With 100,000+ annual overdose deaths in the US, here
A GLP-1 receptor gene variant (rs6923761) alters alcohol reward and brain imaging responses. Pharmacogenomics may predict who benefits from GLP-1 addiction treatment.
Social media reports of GLP-1 users losing interest in gambling and compulsive shopping. The dopamine science supports the possibility — but clinical evidence is thin. Here
There are zero FDA-approved medications for cannabis use disorder. A study in Molecular Psychiatry shows semaglutide associated with 44% reduction in CUD. Here
The Lancet AUD trial showed improved liver biomarkers alongside reduced drinking. GLP-1s also have independent MASLD/MASH data. For people with alcohol-related liver damage, this dual…
From the first rodent amphetamine studies to the 606,434-patient BMJ mega-study. A chronological reference of every major GLP-1 addiction study. Bookmark this.
GLP-1 users described quieting of food noise. Dr. Al-Aly extended it to drug noise. The reframing reflects real neuroscience — and it matters for destigmatizing addiction.
FDA found no increased suicide or self-harm risk in 2.24 million GLP-1 users. Requests removal of warning labels. NIH study found lower suicidal ideation risk. What this means for addiction…
Not approved for addiction yet. Won
Washington University
A living tracker of actively recruiting clinical trials testing semaglutide and other GLP-1 drugs for alcohol, nicotine, opioid, and other addictions. Eligibility, locations, and how to…